XORTX Therapeutics Files September 2024 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Sep 6, 2024 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, compliance, foreign-private-issuer
TL;DR
XORTX files routine 6-K, confirms 20-F annual report filing. Business as usual.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on September 6, 2024, reporting for the month of September 2024. The company, incorporated in Alberta, Canada, is involved in the pharmaceutical preparations industry. This filing is in accordance with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 and indicates the company files annual reports under Form 20-F.
Why It Matters
This filing provides routine updates and confirms XORTX Therapeutics Inc.'s compliance with SEC reporting requirements for foreign private issuers, which is crucial for investor transparency.
Risk Assessment
Risk Level: low — This is a routine SEC filing for a foreign private issuer and does not contain new material financial or operational information that would typically increase risk.
Key Numbers
- 001-40858 — SEC File Number (Identifies the company's registration with the SEC.)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- 001-40858 (dollar_amount) — SEC File Number
- 20240906 (date) — Filing Date
- September 2024 (date) — Reporting Period
- Form 20-F (company) — Annual Report Form
- Form 6-K (company) — Filing Type
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of September 2024.
Which annual report form does XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. files its annual reports under cover of Form 20-F.
What is the SEC File Number for XORTX Therapeutics Inc.?
The SEC File Number for XORTX Therapeutics Inc. is 001-40858.
When was this Form 6-K filed?
This Form 6-K was filed on September 6, 2024.
What is the principal executive office address of XORTX Therapeutics Inc.?
The principal executive office address is 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1.
Filing Stats: 148 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-09-06 17:30:04
Filing Documents
- f6k_090624.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-005101.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: September 6, 2024 /s/ Allen Davidoff Allen Davidoff Chief Executive Officer EXHIBIT INDEX 99.1 News release dated September 6, 2024